VAIL – The Vail Recreation District has selected John Monson, effective Dec. 19, to lead all communication and marketing efforts.VRD Executive Director Mike Ortiz says Monson was the right choice at ...
Daratumumab and hyaluronidase-fihj is now FDA-approved for newly diagnosed multiple myeloma patients ineligible for ASCT, in combination with VRd. The phase 3 CEPHEUS trial showed significant ...
The American Cancer Society estimates that doctors will diagnose multiple myeloma in 34,470 people in the United States in 2022. Multiple myeloma, or myeloma, is a blood cancer that develops in plasma ...
The FDA approved the quadruplet regimen on July 30 for induction and consolidation therapies in patients with newly diagnoses multiple myeloma who are eligible for autologous stem cell transplant.
Johnson & Johnson seeks FDA approval for Darzalex Faspro-based regimen (D-VRd) for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Phase 3 CEPHEUS study shows D-VRd ...
The FDA approved subcutaneous daratumumab-hyaluronidase (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for induction and consolidation in ...
Darzalex addition to VRd improves MRD negativity and PFS in transplant-ineligible multiple myeloma patients, supporting its use as standard care. The CEPHEUS trial showed a 50% increase in MRD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results